TTX-MC138 Shows Survival Benefit in Breast Cancer
BOSTON, Aug. 31, 2026 TransCode Therapeutics announced the publication of new peer-reviewed research reporting a survival benefit for TTX-MC138...
Infectious Diseases
Advertisement
RedHill Advances Opaganib for Ebola Outbreak Response
Raleigh, North Carolina, August 31, 2026 RedHill Biopharma Ltd. announced an update on the emergency development of opaganib as...
FDA Approves Gilead’s Bixlenvo for HIV Treatment
Foster City, California, August 27, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
AskBio Advances Heart Failure Gene Therapy in Phase 2
Durham, North Carolina, August 29, 2026 AskBio Inc. presented baseline characteristics from its Phase 2 GenePHIT clinical trial evaluating...
Moderna Wins FDA Approval for 2026-27 COVID Vaccines
Cambridge, Massachusetts, August 27, 2026 Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved supplemental...
Advertisements
ViiV Healthcare’s Tivicay PD Wins FDA Approval for Kids
LONDON, Aug 26, 2026 The U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) from ViiV Healthcare...
Osivax, GC Biopharma Partner on Next-Gen Flu Vaccine
Lyon, France and Yongin, Republic of Korea, Aug. 26, 2026 Osivax, a clinical-stage biopharmaceutical company developing broad-spectrum influenza vaccines,...
Infex Therapeutics Advances RESP-X Phase IIa Data at ERS 2026
Alderley Park, Cheshire, U.K., August 19, 2026 Infex Therapeutics will present new Phase IIa data for RESP-X (INFEX702) in...
Acurx Advances Ibezapolstat Toward Phase 3 Development
Staten Island, New York, August 17, 2026 Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing antibiotics for difficult-to-treat bacterial...
ArkBio Advances Ziresovir in FDA-Approved Phase II RSV Trial
Shanghai, China, August 14, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that the U.S. Food and Drug Administration...
Advertisement
